Latest News

Friday, February 17, 2017 | Neuromuscular & Immune Disorders

FDA Accepts NDA Filing for MT Pharma’s Investigational ALS Treatment

The FDA accepted the Mitsubishi Tanabe Pharma’s New Drug Application (NDA) for edaravone (MCI-186), an intravenous treatment for amyotrophic lateral sclerosis (ALS). Edaravone is described as a …

Read the full story

Friday, February 10, 2017 | Movement Disorders, Phase 3/4 Trials

Inhaled Levodopa Impresses in Treating Parkinson’s OFF Periods in Phase 3 Study

New phase 3 data suggests that the experimental inhaled levodopa, CVT-301 (Acorda Therapeutics), may offer significant improvement in motor function in individuals with Parkinson’s disease exper…

Read the full story

Friday, February 10, 2017 | FDA Approval/Clearance, Neuromuscular & Immune Disorders

New Corticosteroid Approved for Duchenne Muscular Dystrophy

The FDA approved Emflaza (deflazacort) tablets and oral suspension to treat patients age five years and older with Duchenne muscular dystrophy (DMD). Emflaza is the first FDA approved corticosteroid t…

Read the full story

Tuesday, February 07, 2017 | Neuromuscular & Immune Disorders, Research and Publications

Blood Biomarker for Quick and Accurate Prognosis of MS Identified

A newly discovered blood biomarker may aid physicians in identifying the type of multiple sclerosis (MS) in their patients. In a study recently published in Scientific Reports, investigators evaluated…

Read the full story

Thursday, January 26, 2017 | Healthcare Trends

Burnout Affects 60 Percent of US Neurologists

  More than half of practicing neurologists in the US are experiencing some form of burnout, according to a new study published online in Neurology (January 25). The study involved 1,671 neuro…

Read the full story

Thursday, January 26, 2017 | Phase 3/4 Trials, Research and Publications, Sleep

Investigational Narcolepsy Agent Found Effective for Severely Affected Patients with Cataplexy in Phase 3 Study

Results from a phase 3 controlled trial show that pitolisant (Wakix, Bioproject Pharma) may be efficacious in severely affected narcoleptic patients with cataplexy. Pitolisant is a highly-selective hi…

Read the full story

Wednesday, January 25, 2017 | Research and Publications, Visual & Sensory Disturbances

Validation Study for Potential CTE Detection Blood Test Initiated

Researchers with Exosome Sciences, Inc., are initiating a clinical study involving retired NFL players and a data-supported biomarker candidate to detect and monitor Chronic Traumatic Encephalopathy (…

Read the full story

Wednesday, January 25, 2017 | Dementia & Cognitive Disorders, FDA Approval/Clearance, Product Launches and Updates

Memory Impairment Screening Tool Gains FDA Clearance

The FDA has granted 510(k) clearance to CANTAB Mobile (Cambridge Cognition), a sensitive screening tool for the detection clinically-relevant memory impairment in older adults at the point of care. CA…

Read the full story

Thursday, January 19, 2017 | Pain & Headache, Research and Publications

Lower Vitamin D Levels in Men Linked to Increased Frequency of Headache

Low levels of vitamin D was associated with markedly higher risk of frequent headache in men, according to new findings published in Scientific Reports (Article number: 39697, 2017). Investi…

Read the full story

Thursday, January 19, 2017 | Epilepsy & Seizure Disorders, Personnel/Company News, Product Launches and Updates

Takeda and Ovid Strike Partnership to Develop Investigational Agent for Rare Pediatric Epilepsy

Takeda and Ovid Therapeutics are teaming up for the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel CH24H inhibitor, in rare pediatric epilepsies…

Read the full story

Wednesday, January 18, 2017 | Acquisitions and Mergers, Pain & Headache, Personnel/Company News

Lilly to Acquire Migraine Drug Maker CoLucid

Eli Lilly and Co. is set to acquire CoLucid Pharmaceuticals for $960 million. CoLucid is currently developing lasmiditan, a migraine medicine that could help patients with cardiovascular disease.…

Read the full story

Thursday, January 12, 2017 | Dementia & Cognitive Disorders, Research and Publications

High Levels of Aluminum Found in Brain Tissue of Individuals with Familial Alzheimer’s Disease

A British study has found extremely high levels of aluminum in the tissue of brains of individuals with familial Alzheimer’s disease. Using fluorescence microscopy to identify aluminum, investig…

Read the full story

Thursday, January 05, 2017 | Dementia & Cognitive Disorders, Phase 3/4 Trials, Research and Publications

Neuronix Reveals Data Suggesting Non-invasive TMS Device Improves Cognitive Performance in Alzheimer’s Disease

New findings suggest that an investigational device that combines transcranial magnetic stimulation (TMS) with cognitive training may improve cognitive performance in individuals with Alzheimer&r…

Read the full story

Wednesday, January 04, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

Newly Published Phase 3 Data Boost Efficacy Profile of Ocrevus in Primary Progressive and Relapsing MS

As the FDA continues its review of the Biologics License Application (BLA) for Genentech’s Ocrevus (ocrelizumab), key phase 3 findings reviewing the agent’s safety and efficacy in relapsin…

Read the full story

Wednesday, December 21, 2016 | Dementia & Cognitive Disorders, Research and Publications

Phase 2 Data Finds Pimavanserin Effective and Well Tolerated in Patients with Alzheimer’s Disease Psychosis

Phase 2 Data Finds Pimavanserin Effective and Well Tolerated in Patients with Alzheimer’s Disease Psychosis Acadia Pharmaceuticals has unveiled positive top-line results from its Phase 2 expl…

Read the full story
Load More